Patents Examined by Traviss C. McIntosh, III
-
Patent number: 11944687Abstract: This disclosure relates to an improved process for the preparation of carbohydrate conjugates. The disclosure also relates to carbohydrate conjugated iRNA agents comprising these carbohydrate conjugates, which have improved purity and are advantageous for the in vivo delivery of the iRNA agents.Type: GrantFiled: July 5, 2022Date of Patent: April 2, 2024Assignee: ALNYLAM PHARMACEUTICALS, INC.Inventors: Jayaprakash K. Nair, Alexander V Kel'in, Pachamuthu Kandasamy, Kallanthottathil G Rajeev, Muthiah Manoharan
-
Patent number: 11939349Abstract: A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.Type: GrantFiled: July 20, 2022Date of Patent: March 26, 2024Assignee: GALECTO BIOTECH ABInventors: Fredrik Zetterberg, Kristoffer Peterson, Karl Jansson
-
Patent number: 11939319Abstract: The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.Type: GrantFiled: June 18, 2019Date of Patent: March 26, 2024Assignee: UCB PHARMA GMBHInventors: Cecile Pegurier, Laurent Provins, Alvaro Cardenas, Marie Ledecq, Christa E. Mueller, Joerg Hockemeyer, Ali El-Tayeb, Nader Boshta, Mahmoud Rashed
-
Patent number: 11932666Abstract: Provided is a polymerizable compound represented by a Formula E-1 or Formula E-2 shown in the description. In Formula E-1 or Formula E-2, R1 represents an alkoxy group, —NRN2, a hydroxy group, an aryl group, or an alkyl group, wherein RN each independently represents a hydrogen atom or an alkyl group having 1 to 10 carbon atoms; n represents an integer from 1 to 5; R3 represents a hydrogen atom, an acetyl group, a phenoxyacetyl group, a pivaloyl group, a benzyl group, a 4-methoxybenzyl group, a benzoyl group, a triphenylmethyl group, a 4,4?-dimethoxytrityl (DMTr) group, a 4-methoxytrityl (MMTr) group, a 9-phenylxanthenyl group, a trimethylsilyl group, a cyanomethoxymethyl group, a 2-(cyanoethoxy)ethyl group, or a cyanoethoxymethyl group; and X represents a structure represented by any one of Formula B-1 to Formula B-5 shown in the description.Type: GrantFiled: October 13, 2022Date of Patent: March 19, 2024Assignee: TOKYO UNIVERSITY OF SCIENCE FOUNDATIONInventors: Takeshi Wada, Tatsuya Saito, Yuka Ishii, Yohei Nukaga
-
Patent number: 11926644Abstract: Disclosed is a compound of formula (I): wherein R1, R2, R3, and are as defined herein. Also disclosed are methods for increasing mammalian cell NAD+ production and improving mitochondrial cell densities comprising administering to a cell the compound or a salt thereof.Type: GrantFiled: July 27, 2021Date of Patent: March 12, 2024Assignee: Cornell UniversityInventors: Anthony Sauve, Farheen Sultana Mohammed, Yue Yang
-
Patent number: 11926645Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.Type: GrantFiled: August 26, 2021Date of Patent: March 12, 2024Assignee: Gilead Sciences, Inc.Inventors: Elaine Bunyan, Byoung-Kwon Chun, Kassibla E. Dempah, Hon C. Hui, Rao V. Kalla, Richard L. Mackman
-
Patent number: 11918596Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.Type: GrantFiled: July 21, 2021Date of Patent: March 5, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z. I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel
-
Patent number: 11919921Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.Type: GrantFiled: May 19, 2022Date of Patent: March 5, 2024Assignee: GALECTO BIOTECH ABInventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
-
Patent number: 11903959Abstract: This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.Type: GrantFiled: September 2, 2021Date of Patent: February 20, 2024Assignee: Emory UniversityInventors: George R. Painter, Gregory R. Bluemling, Michael G. Natchus, David Guthrie
-
Patent number: 11897915Abstract: Provided herein are novel sugar derivatives which are intermediates for preparing senolytic agents that selectively kill senescent cells associated with numerous pathologies and diseases, including age-related pathologies and diseases.Type: GrantFiled: September 13, 2022Date of Patent: February 13, 2024Assignee: Rubedo Life Sciences, Inc.Inventors: Paul Keitz, Gus Bergnes, Mark A. Gallop, Marco Quarta
-
Patent number: 11883423Abstract: Disclosed herein are derivatives of nucleobase analogues. The disclosed compounds have a nucleobase moiety and an omega-3 polyunsaturated fatty acid moiety, including pharmaceutically acceptable salt or prodrug thereof. Methods of using these compounds for the treatment of cancers such as pancreatic cancer are also disclosed.Type: GrantFiled: March 14, 2022Date of Patent: January 30, 2024Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Zhengrong Cui, Dharmika Lansakara-P.
-
Patent number: 11879125Abstract: Provided herein, are compositions comprising GaINAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.Type: GrantFiled: March 15, 2023Date of Patent: January 23, 2024Assignee: EMPIRICO INC.Inventors: Darren H. Wakefield, David Rozema, Omri Gottesman
-
Patent number: 11879145Abstract: Disclosed herein are compositions, methods, cells, engineered microorganisms, and kits for increasing the production of proteins or polypeptides comprising one or more unnatural amino acids. Further provided are compositions, cells, engineered microorganisms, and kits for increasing the retention of unnatural nucleic acids encoding the unnatural amino acids in an engineered cell, or semi-synthetic organism.Type: GrantFiled: June 12, 2020Date of Patent: January 23, 2024Assignee: The Scripps Research InstituteInventors: Floyd E. Romesberg, Vivian T. Dien, Aaron W. Feldman, Rebekah J. Karadeema, Lingjun Li, Michael P. Ledbetter, Anne Xiaozhou Zhou
-
Patent number: 11873317Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.Type: GrantFiled: December 26, 2019Date of Patent: January 16, 2024Assignee: GLYCOMIMETICS, INC.Inventors: John L. Magnani, John M. Peterson, Arun K. Sarkar, Yusufbhai U. Vohra, Indranath Ghosh, Jason Nogueira
-
Patent number: 11865129Abstract: The present disclosure relates to an application of anemoside B4 in preparation of drug for treatment or prevention of psoriasis. Anemoside B4 has therapeutic effect on 5% imiquimod-induced psoriatic lesions in mice. Its possible mechanism may be inhibiting inflammation reactions, regulating immune function and inhibiting angiogenesis, and the therapeutic effect may be realized by inhibiting the release of IL-12, IL-17, IL-6 and IL-1? in skin tissue. This study of the present disclosure laid a theoretical foundation for the subsequent development of anemoside B4 into an anti-psoriasis drug of traditional Chinese medicine.Type: GrantFiled: June 2, 2022Date of Patent: January 9, 2024Assignee: GUANGXI XINHAI PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Hongwei Gao, Shilin Yang, Renyikun Yuan, Xiaoran Li
-
Patent number: 11865128Abstract: A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5? position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification.Type: GrantFiled: April 8, 2021Date of Patent: January 9, 2024Assignee: Technion Research & Development Foundation LimitedInventors: Timor Baasov, Dana Atia-Glikin, Jeyakumar Kandasamy, Valery Belakhov
-
Patent number: 11858956Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.Type: GrantFiled: December 17, 2021Date of Patent: January 2, 2024Assignees: Southern Research Institute, Oregon Health & Science University, Washington University in St. Louis, Board of Regents, The University of Texas SystemInventors: Omar Moukha-Chafiq, Ashish Kumar Pathak, Shuklendu D. Karyakarte, Larry D. Bratton, Corinne E. Augelli-Szafran, Michael Diamond, Pei Yong Shi, Alec Jay Hirsch, Jessica Lee Smith, Daniel Streblow, Nicole Haese, Baoling Ying
-
Patent number: 11851655Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.Type: GrantFiled: October 1, 2020Date of Patent: December 26, 2023Assignee: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
-
Patent number: 11851406Abstract: Described are positive allosteric modulators of muscarinic acetylcholine receptor M1 (mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric disorders, or a combination thereof.Type: GrantFiled: June 13, 2019Date of Patent: December 26, 2023Assignee: Vanderbilt UniversityInventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Julie L. Engers, Aaron M. Bender, Madeline Long
-
Patent number: 11851455Abstract: A synthetic dystroglycan oligosaccharide comprising: wherein a repeating disaccharide motif consists of Glucuronic Acid (ClcA) and Xylose (Xyl) having a defined glycosyl connection GlcA-?-(1?3)-Xyl-?-(1?3)-GlcA; wherein either end of the synthetic dystroglycan oligosaccharide is conjugatable with chemical or biological vehicle or support; wherein the non-reducing terminal is conjugatable win any oligosaccharides or groups that can modify a hydroxyl functionality; and wherein the reducing terminal is conjugatable with any tags, oligosaccharides or anything that can modify a hydroxyl functionality.Type: GrantFiled: January 7, 2019Date of Patent: December 26, 2023Assignee: University of Pittsburgh Of The Commonwealth System of Higher EducationInventors: Xinyu Liu, Aniruddha Sasmal